511 filings
Page 2 of 26
8-K
6q30lv7a6ee w7s9dc
9 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
dgn6a57kh5duv
31 May 23
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells
6:44am
8-K
kicsiorecx3wzc
8 May 23
Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer
7:45am
8-K
fpddj8k4 by
1 May 23
MaRKER Announces LeADERSHIP TRANSITION & ProVIdes UPDATE ON OPERATIONAL STRATEGY
7:36am
ARS
xvrrrgt8dh8epmk p1
28 Apr 23
Annual report to shareholders
4:09pm
424B5
frgaxogl
22 Mar 23
Prospectus supplement for primary offering
8:21am
8-K
4xnaf4qkgk sz5urxa5
22 Mar 23
Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results
8:18am
8-K
zmeje
16 Mar 23
Departure of Directors or Certain Officers
4:05pm
8-K
knhzmontoaho
26 Jan 23
Amendments to Articles of Incorporation or Bylaws
4:16pm
424B3
jejgekjvcaect1kbk
3 Jan 23
Prospectus supplement
9:00am
EFFECT
09u0kghyhbw755a023m
3 Jan 23
Notice of effectiveness
12:15am
CORRESP
6c9uk7b9cx4 6t8m
29 Dec 22
Correspondence with SEC
12:00am
UPLOAD
yrmsee3
29 Dec 22
Letter from SEC
12:00am
8-K
3twkrw
13 Dec 22
Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
7:30am
8-K
y18trw qcn
22 Nov 22
Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer
7:15am
8-K
l0wu0fu92ceeu
10 Nov 22
Marker Therapeutics Reports Q3 2022 Operating and Financial Results
4:16pm